Revance Therapeutics (RVNC -5.6%) is down on light volume in early trade on the heels of Allergan’s announced acquisition of Bonti, a developer of fast-acting neurotoxin treatments, including a Phase 2 candidate for frown lines.
Revance plans to file a U.S. application for frown line treatment daxibotulinumtoxinA in H1 2019.
Evolus (EOLS -0.9%) has recently sold off as well.
Previously: Allergan to acquire Bonti for $195M (Sept. 14)
Previously: Evolus continues slide, down 3% (Sept. 13)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.